DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery And Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
Cooperation Between CLIA-Certified Cancer Diagnostics Laboratory and Canadian Tech-Bio Company Will Allow Artificial Intelligence Models to Interrogate World's Largest Primary Tumor Biobank
- DiaGen gains access to 70,000+ primary tumor biobank, including world's largest gynecologic cancer biopsy repository, for therapeutic target discovery/validation
- Fifteen anticancer peptides (ACPs) being leveraged for target identification and comparator for AI-enabled in silico small molecule candidate library creation
- In vitro proof-of-concept for DiaGen's ACPs established in breast cancer cell lines, including triple negative breast cancer, with potential applications in additional tumor types to be evaluated under the partnership based on the pioneering research co-authored by DiaGen Chief AI Officer Mohit Pandey, Ph.D., published in Nature Communications
- Helomics biobank allows for primary tumor therapeutic candidate screening and target engagement confirmation in GI cancer, brain cancer, breast cancer, head and neck cancer, genitourinary cancer, liver cancer, lung cancer, melanoma, mesothelioma, ovarian cancer, pancreatic cancer, sarcomas and uterine cancer
DataMeds AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company"), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform, today announced that its wholly-owned subsidiary Helomics, Inc. (Helomics), a CLIA-certified cancer diagnostics laboratory, has entered into a cancer target discovery and drug candidate optimization partnership with DiaGen.ai, an award-winning, AI-driven drug discovery company based in Vancouver, Canada.
Helomics maintains one of the world's largest repositories of primary tumor specimens (the "Helomics Biobank") with over 70,000 tumor biopsies, including more than 50,000 gynecologic cancer samples, amassed over nearly three decades. Helomics has also developed proprietary cell painting and patient-tumor derived 3D spheroids that represent a test matrix that preserves tumor stroma and correlates to its 2D platform with associated drug response data (commercially available, insurance reimbursed ChemoFx Assay chemotherapy selection laboratory developed test), allowing for a unique high throughput testing approach. By introducing tumor heterogeneity at pre-clinical stages leveraging primary tumor features, Helomics hopes to inform better drug response predictions to enable the selection of drug/tumor combinations and increase the probability of clinical success.
The companies will initially focus on the validation of fifteen cytotoxic peptides identified using the methodology published in Nature Communications and implemented in DiaGen's CYPRESS platform that have already achieved in vitro proof of concept in breast cancer cell lines, including triple negative breast cancer cell lines (the "DiaGen Peptides"), and, in published testing, were at least 5.5-fold less toxic to normal human blood cells than to the cancer cells. The mechanism of action of the DiaGen Peptides has not yet been established. The companies will work jointly to elucidate the mechanism, test the peptides on primary tumors from the Helomics Biobank and protect the intellectual property created from the resulting discoveries. The DiaGen Peptides were identified based on the pioneering research of DiaGen Chief AI Officer Mohit Pandey, Ph.D., published in Nature Communications.
"Being able to access this robust primary tumor biobank and Helomics' proprietary capabilities to identify new therapeutic targets and leverage our proprietary BLACKCOMB artificial intelligence chemical drug discovery platform to design the best candidates for human clinical development is a transformative opportunity for DiaGen," said Dr. Mohit Pandey, Chief AI Officer (CAIO) of DiaGen.ai. "Building upon the foundational methodologies in my recent peer-reviewed research in Nature Communications, we know that the only way for artificial intelligence companies in the biotechnology space to truly differentiate themselves is to train their models on unique, high-dimensional biological data in areas of high unmet medical need. With this agreement, DiaGen is gaining access to an untapped resource of real-world tumor data upon which to build a novel intellectual property portfolio together with Helomics."
Under the terms of the agreement, DiaGen and Helomics will collaborate to perform therapeutic target discovery research and development activities to identify novel breast cancer therapeutic target(s) and evaluate the therapeutic potential of the DiaGen Peptides on primary breast cancer biopsies, including triple negative breast cancer. Upon discovery of the DiaGen Peptides' therapeutic target(s), the companies will work to identify whether this novel mechanism of action is applicable to other cancers in the Helomics Biobank, including GI cancer, brain cancer, head and neck cancer, genitourinary cancer, liver cancer, lung cancer, melanoma, mesothelioma, ovarian cancer, pancreatic cancer, sarcomas, and uterine cancer. Helomics and DiaGen will jointly own the intellectual property created from this target discovery exercise. DiaGen will create a library of drug candidates leveraging its BLACKCOMB artificial intelligence small molecule design platform. Helomics will perform pre-clinical in vitro cell line and primary tumor validation activities to identify the small molecules most suitable for therapeutic development and work together with DiaGen to confirm candidate selection in breast cancer animal models. The companies plan to work to partner the novel cancer drug target(s) and therapeutic candidate(s) with pharmaceutical partners or launch a joint venture to fund their further development.
As part of the agreement, the companies will consummate a share exchange in which DataMEDS will issue 630,000 common shares to DiaGen, (equivalent to 9.9 percent of DataMEDS common shares outstanding as of the date of the agreement) and DiaGen will issue 9.9 percent of its fully diluted common shares outstanding to DataMEDS in consideration. DataMEDS will contribute up to 50 percent of the compute expenses incurred under the agreement in furtherance of research milestones, sourced primarily from its existing compute spend. DiaGen will contribute the cash for the hard costs of the wet lab experiments conducted under the agreement per milestone benchmarks as they are achieved and funded. The total value associated with the transaction is expected to be $1.5M in cash and in-kind contributions through completion of project milestones and target validations to a lead therapeutic drug candidate with animal proof of concept in models of breast cancer, including triple negative breast cancer, and in vitro proof of concept in up to thirteen cancer types.
"We are excited to have identified our first partner that begins the process of monetizing the unique resources in our lab and will help us unlock the tremendous value resident in one of the world's largest curated biobanks while also allowing us to participate in the long-term value creation of biotechnology drug discovery," said Gerald Commissiong, Interim Co-CEO of DataMEDS. "Helomics is also now open to establish new practicing oncologist relationships for its commercially available ChemoFx Assay, as well as re-activate historical relationships, which will help us continue to grow the size and diversity of the Helomics Biobank. Partnering with DiaGen lets us contribute to the creation of groundbreaking new therapies that can improve the standard of care for patients with cancer while allowing us to participate in the value of the new intellectual property created leveraging our unique resources."
The global cancer therapeutics market is projected to grow from $212.58B in 2026 to $501.07B by 2035, according to Precedence Research. The value of validated artificial intelligence derisked targets is expected to be up to $28B according to McKinsey.
About DiaGen AI Inc.
Headquartered in Vancouver, DiaGen AI Inc. is developing a diverse pipeline of AI-powered tools for small molecule and peptide discovery, diagnostics, and delivery. Using its proprietary generative AI Blackcomb and Cypress Protocols, DiaGen aims to de-risk, accelerate, and create value across the global traditional SME drug discovery sector, advancing precision medicine and impacting global human longevity. DiaGen's research has been accepted at NeurIPS, the premier machine learning conference, and the company is a graduate of the Creative Destruction Lab at the University of Washington among other world-wide partnerships.
For more information, visit www.diagen.ai
About DataMEDS AI
DataMEDS AI, Inc., formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA-based commercial clinical molecular diagnostics laboratory focused on the ChemoFx Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions. For more information, visit https://datamedsai.com.
About Helomics Corporation
Helomics Corporation, a wholly owned subsidiary of DataMeds AI, Inc. (NASDAQ:MEDS), operates a CLIA-certified clinical laboratory in Pittsburgh, Pennsylvania, focused on precision oncology. Its flagship ChemoFx Assay tests a patient's live tumor cells against a panel of chemotherapy agents to give oncologists patient-specific information to help inform treatment decisions in gynecologic cancers. ChemoFx is billed under CPT codes 81535 and 81536. Through Predictive Oncology, its Cancer Biomarker Super Intelligence (SI) division, Helomics combines a large annotated biobank of tumor samples, from over 130 tumor types, with artificial intelligence and multi-omic data. It uses these to help pharmaceutical and biotechnology partners predict tumor response and speed up oncology drug discovery and development. The ChemoFx Assay is a laboratory-developed test (LDT) and has not been cleared or approved by the U.S. Food and Drug Administration. For more information, visit https://predictive-oncology.com/.
Source: DataMEDS AI, Inc.